ATS 2024 Final Program

Click on the session title to view the speakers

153

MONDAY • MAY 20

P1231 Prognostic Factors and Outcomes in Lung Transplantation in Interstitial Lung Diseases: Real-world Data From Lung Transplant- and European ILD Registry (eurILDreg) P1232 A Case Series Describing Response to Rabbit Anti-thymocyte Globulin for the Treatment of Bronchiolitis Obliterans Syndrome in Patients With Chronic Lung Allograft Dysfunction P1233 Pulmonary Embolism Following Lung Transplantation: A Single-Center, Descriptive Review P1234 Differentiation Between Benign and Non-benign Pneumatosis Intestinalis After Lung Transplantation: A Single-center Retrospective Study P1235 Analysis of Waitlist Performance and Post-transplant Outcome of Lung Transplant in the Elderly in Korea: A Nationwide Cohort Study P1236 Impact of Augmented Immunosuppression on Survival and Infections in Lung Transplant Recipients

P1242 Safety and Efficacy of Inhaled Pirfenidone (AP01) in the Atlas Open-label Extension Study P1243 The INREAL Study: A Real-World Evaluation of Nintedanib for Changes in Dyspnea and Cough in Chronic PF-ILD Patients P1244 Inhaled Pirfenidone Reduces the Risk of Disease Progression: A Post-hoc Analysis of the Atlas Study P1245 Rapid Antibody Depletion: A Novel Therapeutic Approach for Acute Exacerbation of Interstitial Lung Disease P1246 A Decade of Nintedanib: An Analysis of the FDA Adverse Event Reporting System Database P1247 Tolerance and Efficacy of Dry Powder Inhaler Treprostinil in Pulmonary Hypertension Associated With Interstitial Lung Disease P1248 Interim Analysis of Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis (HALT-IPF): A First-in-Human, Phase 1, Randomized Controlled, Open-label Trial P1249 Pulmonary Vasodilator Therapy in Idiopathic Pulmonary Fibrosis Associated Pulmonary Hypertension P1250 Disparities in Oxygen Initiation for Interstitial Lung Disease in Canada P1251 Differences in E-lung Biomarker Scores Between Treatment Groups in Post-hoc Analysis of the ATLAS Inhaled Pirfenidone Solution (AP01) for IPF Clinical Trial P1252 Lymphangioleiomyomatosis - Long Term Results of Sirolimus Treatment P1253 The Safety and Efficacy of Nintedanib at Various Doses in Idiopathic Pulmonary Fibrosis: A Retrospective Study P1254 A Retrospective Review of Which Agents Controlled Hypercalcemia in a Sarcoidosis Population at a Quaternary Referral Center P1255 Referral of Czech Patients With Idiopathic Pulmonary Fibrosis to a Transplant Center: Data From the Empire Registry P1256 Duration of Effectiveness of Antifibrotic Therapies in Patients With Idiopathic Pulmonary Fibrosis P1257 Radiographic Pattern of Myositis-associated ILD and Predicting Response to Therapy

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B48 NEW TREATMENTS IN DIFFUSE PARENCHYMAL LUNG DISEASE 9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area K (Hall H, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1238 Antifibrotic Dosing Patterns in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources P1239 Single-Agent Oral Therapy of Granulomatous-Lymphocytic Interstitial Lung Disease: A Case Series P1240 The Impact of Frailty on Prescribing Patterns and Medication Tolerability in Patients With Fibrotic Interstitial Lung Disease P1241 The Risk of Drug-induced Liver Injury in Patients With Pulmonary Fibrosis Received Pirfenidone and Nintedanib in Taiwan

ATS 2024 Conference Program • San Diego, CA